|
1
|
Gullick WJ: Prevalence of aberrant
expression of the epidermal growth factor receptor in human
cancers. Br Med Bull. 47:87–98. 1991.PubMed/NCBI
|
|
2
|
Veale D, Ashcroft T, Marsh C, Gibson GJ
and Harris A: Epidermal growth factor receptors in non-small cell
lung cancer. Br J Cancer. 55:513–516. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pollack VA, Savage DM, Baker DA, et al:
Inhibition of epidermal growth factor receptor-associated tyrosine
phosphorylation in human carcinomas with CP-358,774: dynamics of
receptor inhibition in situ and antitumor effects in athymic mice.
J Pharmacol Exp Ther. 291:739–748. 1999.
|
|
4
|
Moyer JD, Barbacci EG, Iwata KK, et al:
Induction of apoptosis and cell cycle arrest by CP-358,774, an
inhibitor of epidermal growth factor receptor tyrosine kinase.
Cancer Res. 57:4838–4848. 1997.PubMed/NCBI
|
|
5
|
Bezjak A, Tu D, Seymour L, et al: Symptom
improvement in lung cancer patients treated with erlotinib: quality
of life analysis of the National Cancer Institute of Canada
Clinical Trials Group Study BR.21. J Clin Oncol. 24:3831–3837.
2006. View Article : Google Scholar
|
|
6
|
Shepherd FA, Rodrigues Pereira J, Ciuleanu
T, et al: Erlotinib in previously treated non-smallcell lung
cancer. N Engl J Med. 353:123–132. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gatzemeier U, Pluzanska A, Szczesna A, et
al: Phase III study of erlotinib in combination with cisplatin and
gemcitabine in advanced mon-small-cell lung cancer: The Tarceva
Lung Cancer Investigation Trial. J Clin Oncol. 25:1545–1552. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Herbst RS, Prager D, Hermann R, et al:
TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774)
combined with carboplatin and paclitaxel chemotherapy in advanced
non-small-cell lung cancer. J Clin Oncol. 23:5892–5899. 2005.
View Article : Google Scholar
|
|
9
|
Kosmidis PA, Dimopoulos MA, Syrigos K, et
al: Gemcitabine versus gemcitabine-carboplatin for patients with
advanced non-small cell lung cancer and a performance status of 2:
a prospective randomized phase II study of the Hellenic Cooperative
Oncology Group. J Thorac Oncol. 2:135–140. 2007. View Article : Google Scholar
|
|
10
|
Langer CJ, O’Byrne KJ, Socinski MA, et al:
Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in
combination with carboplatin versus standard paclitaxel and
carboplatin in the treatment of PS 2 patients with
chemotherapy-naïve advanced non-small cell lung cancer. J Thorac
Oncol. 3:623–630. 2008.PubMed/NCBI
|
|
11
|
O’Brien ME, Socinski MA, Popovich AY, et
al: Randomized phase III trial comparing single-agent paclitaxel
Poliglumex (CT-2103, PPX) with single-agent gemcitabine or
vinorelbine for the treatment of PS 2 patients with
chemotherapy-naïve advanced non-small cell lung cancer. J Thorac
Oncol. 3:728–734. 2008.PubMed/NCBI
|
|
12
|
Lilenbaum R, Villaflor VM, Langer C, et
al: Single-agent versus combination chemotherapy in patients with
advanced non-small cell lung cancer and a performance status of 2:
prognostic factors and treatment selection based on two large
randomized clinical trials. J Thorac Oncol. 4:869–874. 2009.
View Article : Google Scholar
|
|
13
|
Quoix E, Oster V, Westeel E, et al: Weekly
paclitaxel combined with monthly carboplatin versus single agent
therapy in patients age 70 to 89: IFCT-0501 randomized phase III
study in advanced non-small cell lung cancer (NSCLC). J Clin Oncol.
28(Suppl S18): abs. 122010.
|
|
14
|
Mok TSK, Wu Y-L, Yu C-Y, et al:
Randomized, placebo-controlled Phase II study of sequential
erlotinib and chemotherapy as first-line treatment for advanced
non-small cell lung cancer. J Clin Oncol. 27:5080–5087. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Moore MJ, Goldstein D, Hamm J, et al:
Erlotinib plus gemcitabine compared with gemcitabine alone in
patients with advanced pancreatic cancer: a phase III trial of the
National Cancer Institute of Canada Clinical Trials Group. J Clin
Oncol. 25:1960–1966. 2007. View Article : Google Scholar
|
|
16
|
Pocock SJ and Simon R: Sequential
treatment assignment with balancing for prognostic factors in the
controlled clinical trials. Biometrics. 31:103–115. 1975.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumours. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pérez-Soler R, Chachoua A, Hammond L, et
al: Determinants of tumor response and survival with erlotinib in
patients with non-small cell lung cancer. J Clin Oncol.
22:3238–3247. 2004.PubMed/NCBI
|
|
19
|
Stinchcombe T, Bradford DS, Lee CB, et al:
Preliminary results of a randomized phase II trial of first-line
treatment of gemcitabine (G) versus erlotinib (E) versus
gemcitabine and erlotinib (GE) in patients 70 years or older with
advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 28(Suppl
S15): abs. 75762010.
|
|
20
|
Li T, Ling YH, Goldman ID and Perez-Soler
R: Schedule-dependent cytotoxic synergism of pemetrexed and
erlotinib in human non-small cell lung cancer cells. Clin Cancer
Res. 13:3413–3422. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Davies AM, Hesketh PJ, Beckett L, et al:
Pharmacodynamic separation of erlotinib and docetaxel (DOC) in
advanced non-small cell lung cancer (NSCLC): Overcoming
hypothesized antagonism. J Clin Oncol. 25(Suppl S18): abs.
76182007.
|
|
22
|
Davies AM, Ho C, Beckett L, et al:
Intermittent erlotinib (ERL) in combination with pemetrexed (PEM):
phase I schedules designed to achieve pharmacodynamic separation. J
Clin Oncol. 26(Suppl): abs. 80322008.
|
|
23
|
Li T, Lara PN Jr, Mack PC, Perez-Soler R
and Gandara D: Intercalation of erlotinib and pemetrexed in the
treatment of non-small cell lung cancer. Curr Drug Targets.
11:85–94. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gridelli C, Morabito A, Gebbia V, et al:
Cetuximab and gemcitabine in elderly or adult PS2 patients with
advanced non-small-cell lung cancer: the cetuximab in advanced lung
cancer (CALC1-E and CALC1-PS2) randomized phase II trials. Lung
Cancer. 67:86–92. 2010. View Article : Google Scholar : PubMed/NCBI
|
